Labetalol vs. Methyldopa: Pregnancy Hypertension Treatment
- Labetalol shows advantage over methyldopa and nifedipine in hypertensive pregnancies | Image Credit: © Andrey Popov - © Andrey Popov - stock.adobe.com.
- A new meta-analysis published in the American Journal of Obstetrics & Gynecology suggests labetalol may modestly reduce preeclampsia and preterm birth risks compared with methyldopa or nifedipine, though...
- Hypertensive disorders of pregnancy (HDP), including chronic hypertension, gestational hypertension, and preeclampsia, affect approximately 10% of pregnancies and increase the risk of adverse maternal and neonatal outcomes.
Okay, here’s a draft article based on the provided text, formatted as requested, with the elements you specified. I’ve aimed for a clear, informative, and well-structured piece.
“`html
Labetalol May offer Advantages in Managing Hypertensive Pregnancies
Labetalol shows advantage over methyldopa and nifedipine in hypertensive pregnancies | Image Credit: © Andrey Popov – © Andrey Popov – stock.adobe.com.
A new meta-analysis published in the American Journal of Obstetrics & Gynecology suggests labetalol may modestly reduce preeclampsia and preterm birth risks compared with methyldopa or nifedipine, though all 3 oral antihypertensives remain broadly safe and effective.1
Hypertensive disorders of pregnancy (HDP), including chronic hypertension, gestational hypertension, and preeclampsia, affect approximately 10% of pregnancies and increase the risk of adverse maternal and neonatal outcomes. Oral antihypertensives such as methyldopa, labetalol, and nifedipine are commonly used, but head-to-head comparisons remain limited.
“Consequently, it is relevant to re-analyze existing data on the effects of oral antihypertensive agents in pregnancy on mother and child,” wrote investigators.
Comparing Oral Antihypertensive Agents
The systematic review and network meta-analysis aimed to compare the impacts of nifedipine, labetalol, and methyldopa on maternal and neonatal outcomes in pregnancies impacted by HDP. The analysis included randomized trials comparing these oral agents.
Trials were eligible if they reported maternal or neonatal outcomes such as severe hypertension, preeclampsia, eclampsia, maternal mortality, preterm birth, birthweight, small-for-gestational-age infants, Apgar scores, or neonatal death. Data were pooled using a random-effects network meta-analysis to capture both direct and indirect comparisons.
Study durations ranged from early pregnancy until delivery, with participants receiving one of the three study antihypertensive agents. Risk of bias was evaluated using Cochrane criteria, with most studies classified as low to moderate